Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumor 3Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumors 1Solid Tumor 1Locally Advanced or Metastatic Solid Tumors 1HER2 Positive Advanced Solid Tumors 1Cervical Adenocarcinoma 1Advanced or Metastatic Solid Tumors 1

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 9Bevacizumab 8toripalimab 7senaparib 7Fluorodeoxyglucose F18 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Fluorouracil 6Gemcitabine 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Carboplatin 4spartalizumab 3sintilimab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × Albumin-Bound Paclitaxel × Other solid neoplasm × Clear all
NCT00820768 2018-04-11

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Celgene

Phase 1 Withdrawn
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡